Indeed, differences in DCE-PWI parameters between the two IDH genotypes of gliomas have been confirmed in numerous studies, and these parameters have demonstrated excellent performance in predicting IDH mutation status [33–35]. The gene discussed is IDH2; the disease is central nervous system cancer.